Browsing by Author "Canan, Handan"

Now showing 1 - 12 of 12

Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion
(2016) Coban-Karatas, Muge; Altan-Yaycioglu, Rana; Ulas, Burak; Sizmaz, Selcuk; Canan, Handan; Sarıtürk, Cagla; 27275430
AIM: To evaluate central macular thickness (CMT) and mean choroidal thickness (MCT) in eyes with branch retinal vein occlusion (BRVO), before and after ranibizumab treatment using spectral domain -optical coherence tomography (SD-OCT). METHODS: Forty -two patients with unilateral BRVO and macular edema were included in this study. There were 25 men and 17 women. Using SD-OCT, choroidal thickness was measured at 500 mu m intervals up to 1500 mu m temporal and nasal to the fovea. MCT was calculated based on the average of the 7 locations. All the eyes with BRVO were treated with intravitreal ranibizumab (0.5 mg/0.05 mL). Comparisons between the BRVO and fellow eyes were analyzed using Mann-Whitney test. Pre-injection and post-injection measurements were analyzed using Wilcoxon test and repeated measure analysis. RESULTS: At baseline, there was a significant difference between the BRVO and fellow eyes in MCT [BRVO eyes 245 (165-330) mu m, fellow eyes 229 (157-327) mu m] and CMT [BRVO eyes 463 (266-899) mu m, fellow eyes 235 (148-378) mu m (P=0.041, 0.0001, respectively)]. Following treatment, CMT [295 (141-558) mu m] and MCT [229 (157329) mu m] decreased significantly compared to the baseline measurements (P=0.001, 0.006, respectively). Also BCVA (logMAR) improved significantly (P=0.0001) in the BRVO eyes following treatment. After treatment CMT [BRVO eyes 295 (141-558) mu m, fellow eyes 234 (157-351) mu m] and MCT [BRVO eyes 229 (157-329) mu m, fellow eyes 233 (162-286) mu m] values did not reveal any significant difference in BRVO eyes and fellow eyes (P=0.051, 0.824, respectively). CONCLUSION: In eyes with BRVO, CMT and MCT values are greater than the fellow eyes, and decrease significantly following ranibizumab injection.
Effect of diluted povidone iodine in adenoviral keratoconjunctivitis on the rate of subepithelial cornea infiltrates
(2019) Altan-Yaycioglu, Rana; Sahinoglu-Keskek, Nedime; Canan, Handan; Coban-Karatas, Muge; 31544037; AAG-3306-2019; AAL-4440-2020
AIM: To evaluate the clinical characteristics of adenoviral keratoconjunctivitis, the management modalities, as well as the incidence of subepithelial corneal infiltrates (SEI). METHODS: Patients with characteristic clinical symptoms and signs, who presented to our clinic within the first week of symptoms and received the diagnosis of adenoviral keratoconjunctivitis between January 2013 and April 2016, were included in the study. A total of 211 patients were included in the study. Patients were evaluated for the incidence of clinical signs, late complications, management preferences, and the effect of diluted povidone-iodine (d-PVP-I) 2%. RESULTS: Patients' mean age was 33.03 +/- 14.76y. We observed an increase in the number of cases according to the years. At presentation and/or early follow-up, the clinical signs were conjunctival hyperemia (100%), conjunctival follicules (79.1%), edema of the eyelids (39.3%), chemosis (16.1%), pseudomembrane formation (16.6%), and corneal epitheliopathy (29.9%). During late follow-up 13.3% patients developed conjunctival subepithelial fibrosis, and 39.8% developed SEI. A significant decrease in the incidence of SEI development was observed in patients who used d-PVP-I 2% (P=0.032; 33.3% vs 45.9%, respectively in patients who received d-PVP-I 2% and who did not). CONCLUSION: Adenoviral keratoconjunctivitis has a tremendous effect on patient's comfort and abilities in short-term. Additionally, almost half of the patients develop visual problems related to SEI. According to our clinical experience, using d-PVP-I 2% in the first days of adenoviral keratoconjunctivitis might be helpful in reducing the risk of SEI as a complication.
Effect of Latanoprost on Choroidal Thickness
(2018) Sahinoglu Keskek, Nedime; Canan, Handan; 0000-0002-5877-6536; 0000-0001-8544-103X; 29750717; AAB-6394-2021; T-4258-2017
Purpose:The purpose of this study was to evaluate the changes in choroidal thickness during the use of latanoprost eyedrops which shift fluid to the suprachoroidal space and change choroidal perfusion.Materials and Methods:This prospective study included 34 eyes of 17 bilateral glaucoma or ocular hypertensive patients who had no previous hypotensive therapy. Each patient had both eyes treated with latanoprost. Each patient also underwent a complete ophthalmological examination and optical coherence tomography measurement. Choroidal thickness measurements by optical coherence tomography were carried out on the first visit before latanoprost use and at time intervals of 7 and 30 days of therapy.Results:The patients' mean age was 62.311 years (range, 30 to 83y). Of 17 patients, 7 were female individuals. There were no significant differences in central choroidal thicknesses at the fovea, or at each point within the horizontal nasal and temporal quadrants between visits (P<0.05 for all comparisons).Conclusions:The current study showed that choroidal thickness does not change after latanoprost therapy. However, the choroidal changes of anterior part of the eye can be effected by the latanoprost therapy. Future studies investigating the anterior part of the eye and focusing on both choroidal perfusion and choroidal thickness may give additional information concerning the mechanism of action.
Epidermoid Cyst of Orbit in a Newborn
(2015) Canan, Handan; Altan-Yaycioglu, Rana; Bal, Nebil; Torer, Birgin; Cetinkaya-Cakmak, Bilin; Gulcan, Hande; 26075126
A 3-day-old male newborn presented with a severe proptosis of the left eye leading to exposure keratopathy. He underwent debulking of the cyst and biopsy of the tumour and received the pathological diagnosis of epidermoid cyst of orbit. Clinicopathological features of this rare disease are discussed.
Influence of Glycosylated Hemoglobin on The Choroidal Thickness
(2018) Sahinoglu-Keskek, Nedime; Altan-Yaycioglu, Rana; Canan, Handan; Coban-Karatas, Muge; https://orcid.org/0000-0001-8544-103X; https://orcid.org/0000-0002-9139-8848; https://orcid.org/0000-0002-5877-6536; https://orcid.org/0000-0002-5877-6536; 28766280; T-4258-2017; AAG-3306-2019; AAB-6394-2021; AAB-6394-2021
PurposeThe aim of the study reported here was to assess the influence of serum HbA1c levels on foveal choroidal thickness in diabetic patients.MethodsA total of 122 eyes from 122 patients who had type 2 DM were studied in this prospective, cross-sectional study. Patients were divided into three groups: 43 patients (43 eyes) without diabetic retinopathy (NDR), 39 patients (39 eyes) with diabetic retinopathy and no macular edema (DR/ME-), 40 patients (40 eyes) with diabetic retinopathy and macular edema (DR/ME+). Central foveal thicknesses and subfoveal choroidal thicknesses were noted. Subfoveal choroidal thickness measurement was taken perpendicularly from the outer part of the retinal pigment epithelial layer to the line corresponding to the choroidal-scleral junction. Serum glycosylated hemoglobin (HbA1c) levels were evaluated.ResultsNo significant differences in age, gender, pseudophakia were observed between the groups. There was no significant difference in HbA1c value among the three diabetic groups. Mean foveal choroidal thickness was 270.0942.41 in NDR group, 243.18 +/- 30.21 in DR/ME- group and 250.90 +/- 40.06 in DR/ME+ group. Mean foveal choroidal thickness in NDR group was significantly different from DR/ME- group. There was no statistically significant difference between the other groups among foveal choroidal thicknesses. There was no correlation between HbA1c and foveal choroidal thickness. Multiple regression analyses of two diabetic retinopathy groups showed no significant correlation between foveal choroidal thickness and HbA1c and also no significant correlation between foveal choroidal thickness and duration of diabetes.Conclusions p id="Par4Serum HbA1c levels were not correlated with foveal choroidal thickness. Choroidal thickness is effected by several factors as axial length, age and systemic diseases.
Interexaminer Reproducibility of Optical Coherence Tomography for Measuring the Tear Film Meniscus
(2014) Canan, Handan; Altan-Yaycioglu, Rana; Ulas, Burak; Sizmaz, Selcuk; Coban-Karatas, Muge; https://orcid.org/0000-0002-5877-6536; https://orcid.org/0000-0002-9139-8848; 24749829; AAB-6394-2021; AAG-3306-2019
Purpose: New optical coherence tomography (OCT) devices with anterior segment module are able to measure the tear meniscus height (TMH) and tear meniscus area (TMA). Since the borders of the area and the height are to be marked by an examiner, the measurements are prone to be subjective. Herein, we aimed to evaluate the interexaminer reproducibility of the tear meniscus measurements with OCT. Materials and Methods: In this prospective cross-sectional study, both eyes of 300 consecutive patients with and without dry eye were studied. Following routine ophthalmologic examination, tear-film OCT images were obtained. Two examiners, who were unaware of the other examiner's results, measured the TMH (i. e. the line connecting the intersection of the meniscus with the cornea/sclera and eyelid) and cross-sectional TMA. The reliability and correlation of the two examiners' results were assessed. Results: Four right and six left eyes were excluded from the final analysis, so a total of 590 eyes were evaluated. The mean difference of the two examiners' measurements of both eyes was - 0.001 +/- 0.027mm(2) in TMA, and - 21.29 +/- 39.95 mm in TMH. An agreement between the two examiners was found regarding TMA and TMH measurements for right and left, as well as both eyes (Cronbach's alpha > 0.900, for all). Also, the correlation between both variables was high (inter item correlation matrix > 0.840, for all). Conclusions: We showed a strong statistical agreement for both TMA and TMH measurements. According to our results, we believe that FD-OCT device is dependable in measuring the TMA and TMH values, given that its results are reproducible.
Measurements of Retinal Nerve Fiber Thickness and Ganglion Cell Complex in Neurofibromatosis Type 1, with and Without Optic Pathway Gliomas: A Case Series
(2018) Sahinoglu-Keskek, Nedime; Altan-Yaycioglu, Rana; Canan, Handan; Coban-Karatas, Muge; Erbay, Ayse; Yazici, Nalan; Alkan, Ozlem; https://orcid.org/0000-0001-8544-103X; https://orcid.org/0000-0002-9139-8848; https://orcid.org/0000-0002-5877-6536; https://orcid.org/0000-0001-7526-3460; 29185816; T-4258-2017; AAG-3306-2019; AAB-6394-2021; AAM-5138-2021; AAM-4169-2021
Purpose: The aim of this study was to investigate differences in retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thicknesses in neurofibromatosis 1 (NF1) cases, with and without optic pathway gliomas (OPGs). Materials and Methods: In total, 33 eyes of 33 subjects were evaluated in this prospective observational case series. Twenty-one patients with a diagnosis of NF1 were enrolled. Patients with NF1 and OPGs were included in Group 1 (n=9), and patients with NF1 without OPGs were included in Group 2 (n=12). The control group (Group 3) was comprised of 12 age- and sex-matched subjects with no history of ophthalmic or systemic diseases. All of the subjects underwent complete ophthalmic examinations, including best-corrected visual acuity (BCVA), slit lamp microscopy, and indirect ophthalmoscopy. Additionally, optical coherence tomography (OCT) measurements were obtained. Results: There were no statistically significant between-group differences in age and sex (p=0.227 and 0.986, respectively). The average RNFL thickness in Group 1 (NF1 patients with OPGs) was significantly lower than in Groups 2 and 3 (86.6 +/- 22.5, 107.4 +/- 6.65, and 108.4 +/- 5.05 mu m, respectively; p=0.001). Furthermore, the average GCC thickness in Group 1 was significantly lower than in Groups 2 and 3 (78.6 +/- 16.3, 94.8 +/- 3.55, and 94.9 +/- 3.82 mu m, respectively; p<0.001). Conclusions: Both RNFL and GCC thicknesses were significantly lower in NF1 patients with OPGs. The use of OCT to quantify damage to the visual pathway may enable earlier detection of OPGs in NF1 patients.
Orbital Dermis-Fat Graft Transplantation: Results in Primary and Secondary Implantation
(2015) Karatas, Muge Coban; Yaycioglu, Rana Altan; Canan, Handan
Objectives: Autologous dermis fat graft (DFG) is being used in both primary and secondary socket surgeries. In the present study, we aimed to evaluate patients' satisfaction and possible intra- and postoperative complications in patients who had DFG transplantation. Materials and Methods: In this retrospective study, the results of 17 patients who were operated between October 2008 and October 2012 were evaluated. Of these cases, 7 had primary and 10 had secondary DFG. Patient satisfaction was evaluated by asking the patients to fill out a questionnaire graded from 1 (not satisfied) to 4 (very satisfied). Additionally, the incidence of complications and requirement for another operation was noted. Results: The average patient age was 30.5 +/- 17.9 years. Patients with primary grafts were 100% satisfied with the outcome and could wear their prosthesis without any discomfort. In this group, one patient had delay in epithelialisation of the graft and ptosis, which was treated with frontal sling surgery and artificial tears. In patients with secondary grafts, 6 patients (60%) were satisfied with the outcome. Four patients were not satisfied from the result. One had inferior lid laxity; however, after lateral tarsal strip surgery, she could wear her prosthesis. Another patient developed inferior forniceal adhesion. He was treated with mucous membrane grafting and artificial tears and could wear his prosthesis. One patient had infection and contraction of the socket due to inappropriate postoperative medication use. Following repeated DFG transplantation, he was able to wear his prosthesis. Another patient had fat atrophy prior to secondary DFG transplantation and developed atrophy of the graft following surgery. Her family refused additional surgery. This patient could not wear any prosthesis. Conclusion: According to our results, we believe that DFG transplantation is successful in primary implantation. In secondary cases, correct patient selection is important to achieve good outcome.
The relationship of central corneal thickness with the status of diabetic retinopathy
(2020) Canan, Handan; Sahinoglu-Keskek, Nedime; Altan-Yaycioglu, Rana; 0000-0001-8544-103X; 0000-0002-5877-6536; 32513125; T-4258-2017; AAB-6394-2021
Background To compare central corneal thickness (CCT) values measured by three different devices: slit-scanning topography (SST), ultrasonic pachymetry (UP), and optical coherence tomography (OCT) in diabetic eyes and compare the CCT values in patients with and without diabetic retinopathy. Methods Ninety-six patients with diabetes mellitus were included in this prospective study and divided into two groups according to the presence of diabetic retinopathy, as Group I with retinopathy and Group II without. The CCT of 96 eyes was measured by three different devices; SST (Orbscan II), UP and OCT. The results of CCT measurements with three different devices were compared. Also, the intergroup differences in CCT measurements were evaluated. Results The CCT was statistically insignificantly different between the two groups. Although the three methods of CCT measurements correlated well with each other, SST showed significantly (p < 0,0001) higher CCT results compared to both UP and OCT. Conclusions According to our results, neither the duration of DM nor the presence of diabetic retinopathy did have a significant effect on the CCT. The CCT values obtained with three devices were all in correlation. However, the results of SST were significantly higher compared to the other two. Our findings emphasize the value anterior segment OCT in CCT measurements, since it is a non-contact method and correlate very well with UP.
Retinal and Choroidal Thickness Changes After Single Anti-VEGF Injection in Neovascular Age-Related Macular Degeneration: Ranibizumab vs Bevacizumab
(2014) Sizmaz, Selcuk; Kucukerdonmez, Cem; Kal, All; Pinarci, Eylem Yaman; Canan, Handan; Yilmaz, Gursel; https://orcid.org/0000-0002-5877-6536; https://orcid.org/0000-0002-2589-7294; 24803153; AAB-6394-2021; AAK-6987-2021
Purpose: To evaluate and compare the effects of single intravitreal injection of ranibizumab and bevacizumab on central retinal and choroidal thickness in patients with neovascular age-related macular degeneration (AMD). Methods: Forty eyes of 40 patients with neovascular AMD that underwent intravitreal injection of vascular endothelial growth factor inhibitors (anti-VEGFs) were included. Patients were randomized into 2 groups: 20 eyes received ranibizumab and 20 eyes received bevacizumab injection. Central retinal and choroidal thicknesses of all eyes at baseline and 1 month postinjection scans were measured with Fourier-domain optical coherence tomography (OCT). Student t test and Mann-Whitney U test were used to compare the data. Results: The mean central retinal thickness (CRT) showed significant decrease after single injection of ranibizumab (from 345.0 mu m to 253.5 mu m, p<0.01) and bevacizumab (from 329.5 mu m to 251.0 mu m, p<0.01) at the first month, respectively. There was no significant difference regarding the CRT change between groups (p = 0.39). The mean choroidal thickness decreased from 158.6 mu m (115-317) to 155.5 mu m (111-322) in the ranibizumab group and from 211.5 mu m (143-284) to 201.5 mu m (93-338) in bevacizumab group. The decrease was not significant between groups (p = 0.35). Conclusions: Intravitreal injection of both ranibizumab and bevacizumab provided a significant decrease in CRT; however, the agents caused no significant change in choroidal thickness. Additionally, no difference between ranibizumab versus bevacizumab was observed related to macular edema inhibition.
Role of the Hereditary Thrombophilic Abnormalities in Retinal Vein Occlusions
(2015) Canan, Handan; Demircan, A.Nihal
Purpose: The aim of our study was to evaluate the relation between hereditary thrombophilic factors leading to coagulation disorders and retinal vein occlusion (RVO). Material and Methods: A total of 45 consecutive patients with RVO group and 42 healty subjects (Control group) were enrolled. The mean follow-up period was 15.2 +/- 5.5 months. The following investigations were performed in both groups: Factor V Leiden (FVL), prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) enzyme mutations, antithrombin III, protein C and S activities, fibrinogen, factor VII and VIII levels, D-dimer, activated partial thromboplastin time and prothrombin time/INR, complete blood count, ESR and blood biochemistry. Results: Factor V leiden heterozygote mutation was found in four (9%) patients in RVO and one (2.4%) in Control groups. Homozygote FVL mutation and PT G20210A mutation were not found in neither of the groups. In the RVO group, 26 patients (57.8%) had MTHFR C677T heterozygote mutation and four (8.9%) had homozygote mutation. In the Control group 14 (33.3%) patients had MTHFR C677T heterozygote mutation and four (9.5%) had homozygote mutation. There was a significant difference in MTHFR C677T genotype distribution between the 2 groups (p = 0,032). The serum triglyceride, glucose, fibrinogen and ESR levels were significantly higher in patients compared to the controls Conclusion: We believe that, in addition to all related systemic and ophthalmological investigations, hematological screening tests to detect hypercoagulation should be performed while investigating the etiology in patients with RVO.
Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
(2014) Canan, Handan; Sizmaz, Selcuk; Altan-Yaycioglu, Rana; Sariturk, Cagla; Yilmaz, Gursel
Purpose: To describe 1-year clinical results of intravitreal ranibizumab treatment in patients with choroidal neovascularization secondary to exudative age-related macular degeneration (AMD) and to evaluate whether early treatment is a predictive value for prognosis of the disease. Materials and methods: Clinical records were retrospectively reviewed of 104 eyes that underwent intravitreal ranibizumab therapy for exudative AMD. Patients were divided into two groups according to their symptom duration: group 1,,1 month; and group 2, 1-3 months. After three monthly injections, patients were examined monthly, and subsequent injections were performed as needed. Results: There were 43 female (48.9%) and 45 males (51.1%). The follow-up time was 13.7 +/- 1.9 (12-19) months. The mean logarithm of minimum angle of resolution best-corrected visual acuity (BCVA) improved significantly, from 0.45 +/- 0.639 at baseline to 0.08 +/- 0.267 at 12 months in group 1, and from 1.06 +/- 0.687 at baseline to 0.75 +/- 0.563 at 12 months in group 2. The increase in BCVA was statistically significant in group 1 (P=0.009). The mean central retinal thickness (CRT) decreased significantly, from 355.13 +/- 119.93 mu m at baseline to 250.85 +/- 45.48 mu m at 12 months in group 1, and from 371.88 +/- 91.047 mu m at baseline to 268.61 +/- 53.51 mu m at 12 months in group 2. The decrease in CRT was statistically significant in group 1 (P=0.001). Conclusion: Intravitreal ranibizumab therapy was effective in significantly increasing mean BVCA and reducing CRT. Shorter duration of AMD, as measured by the subjective duration of visual symptoms, is associated with better visual outcome after treatment.